IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Emery, Paul; Keystone, Edward; Tony, Hans‐Peter; Cantagrel, Alain; van Vollenhoven, Ronald; Sánchez, Antonio; Alecock, Emma; Lee, J.; M. Kremer, Joel

doi:10.1136/ard.2008.092932

Public

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Published in Annals of the Rheumatic Diseases • Jul 15, 2008

Authors:

Paul Emery

Edward Keystone

Hans‐Peter Tony

Abstract

OBJECTIVES: The phase III RADIATE study examined the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to tumour necrosis factor (TNF) antagonist therapy. METHODS: 499 patients with inadequate response to one or more T...

Subject

Medicine

Tocilizumab

Rheumatoid arthritis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!